RxDoctor Payments Data

Timothy Muir, MD

Internal Medicine · Falls Church, VANPI 1518012806

Payments from drug & device makers

$477in general payments, 2019–2025

Across 8 payments — averaging $59.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$261
  • AstraZeneca$142
  • Boehringer Ingelheim$26
  • Medtronic$25
  • Exact Sciences$24

What the payments were for

  • Food & beverage$477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$477 in reported general payments places this provider in the 65th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$255,260
Medicare patients
643
Services billed
3,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$39,808
OzempicSemaglutide24$32,105
FarxigaDapagliflozin Propanediol29$29,220
XareltoRivaroxaban23$28,723
JanuviaSitagliptin Phosphate24$26,219
MounjaroTirzepatide13$12,226
JardianceEmpagliflozin14$10,129
SymbicortBudesonide/Formoterol Fumarate14$5,585
Atorvastatin Calcium555$5,440
BrilintaTicagrelor13$4,909
Bupropion XlBupropion Hcl40$3,771
Tamsulosin Hcl166$3,279
Levothyroxine Sodium236$3,261
Losartan Potassium266$2,673
Metoprolol Succinate145$2,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort, Brilinta$142$39,71456 claims
Novo NordiskOzempic$261$32,10524 claims
Boehringer IngelheimJardiance$26$10,12914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →